Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.
Neurogene Inc. (Nasdaq: NGNE) generates news primarily around its gene therapy programs for rare neurological diseases, with a central focus on NGN-401 for Rett syndrome. As a clinical-stage company, Neurogene regularly issues updates on clinical trial progress, interim data, regulatory interactions and corporate developments.
Recent press releases highlight multiple milestones for NGN-401, including dosing of participants in the Embolden registrational trial, initiation of numerous U.S. clinical trial sites, and positive interim data from the Phase 1/2 trial in pediatric and adolescent/adult cohorts. These updates describe multidomain, durable functional gains and developmental milestone acquisition in females with Rett syndrome, along with safety observations at the 1E15 vg dose.
Visitors to this NGNE news page can review announcements on trial design for Embolden, preclinical data comparing intracerebroventricular and intrathecal lumbar delivery, and regulatory designations from the FDA, EMA and UK MHRA. Neurogene also reports on participation in healthcare and genetic medicines conferences, where management presents company overviews and clinical data, as well as on financial results and cash runway disclosures through quarterly earnings releases.
Additional news items cover corporate matters such as inducement grants under Nasdaq Listing Rule 5635(c)(4) and updates furnished via Form 8-K. For investors and followers of Rett syndrome research, the NGNE news stream provides a consolidated view of Neurogene’s clinical progress, regulatory status and operational execution around NGN-401 and its broader gene therapy platform over time.
Neurogene (Nasdaq: NGNE) announced that its Compensation Committee approved inducement grants of non-qualified stock options totaling 4,860 shares to two new employees, with a grant date of December 2, 2025.
The options were issued under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing price of NGNE common stock on the grant date. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date and 1/48 of the award each month thereafter, subject to continued employment.
Neurogene (Nasdaq: NGNE) reported third quarter 2025 results and program updates on November 14, 2025. The company reported $265.4 million in cash, cash equivalents and short-term investments as of September 30, 2025, which it says funds operations through the first quarter of 2028. Clinical updates highlighted updated interim Phase 1/2 pediatric data for NGN-401 in Rett syndrome showing multidomain, durable gains with an aggregate 35 developmental milestones/skills gained across 8 pediatric participants as of an October 30, 2025 cutoff.
Neurogene dosed the first participant in the Embolden registrational trial and has initiated 12 of 13 sites with complete enrollment expected in 3–6 months. Preclinical data presented support intracerebroventricular (ICV) delivery for broader brain biodistribution versus intrathecal lumbar (IT-L).
Neurogene (Nasdaq: NGNE) reported positive interim Phase 1/2 data for its NGN-401 gene therapy in the pediatric Rett syndrome cohort (data cutoff Oct 30, 2025). All 8 pediatric participants showed functional gains across core domains with an aggregate 35 developmental milestones/skills gained and durable, multidomain improvements observed up to 24 months post treatment. Safety (N=10) at the 1E15 vg dose was generally well-tolerated; treatment-related adverse events were Grade 1–2 and no HLH was observed. Additional clinical data is planned for 2026, and management will discuss results at the Stifel 2025 Healthcare Conference webcast on Nov 12, 2025 at 4:40 p.m. ET.
Neurogene (Nasdaq: NGNE) announced that the first participant was dosed in the Embolden registrational trial of NGN-401 for Rett syndrome on November 6, 2025. Embolden is a single-arm, open-label, baseline-controlled study evaluating a 1E15 vg intracerebroventricular dose in 20 females ages ≥3.
The company initiated 12 of 13 U.S. sites and expects to complete enrollment within three to six months. Management will present Phase 1/2 interim data at the Stifel 2025 Healthcare Conference on November 12, 2025, with a webcast and temporary replay available via investor relations.
Neurogene (Nasdaq: NGNE) announced an inducement equity grant approved by its Compensation Committee on November 4, 2025. The company granted non-qualified stock options to purchase 1,185 shares to one newly hired employee under the 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price on the grant date and vest over four years: 25% at the first anniversary of the vesting commencement date and the remaining 75% in equal installments every three months over the following 36 months, subject to continued employment.
Neurogene (NASDAQ: NGNE) completed discussions with the FDA on its Embolden™ registrational protocol and plans to initiate dosing in Q4 2025. The trial is expected to enroll across 13 sites to support rapid recruitment. The company highlighted new NHP data showing intracerebroventricular (ICV) delivery of NGN-401 yields superior transgene RNA expression in brain regions relevant to Rett syndrome versus intrathecal lumbar (IT-L) at clinically relevant doses, while showing comparable peripheral exposure. Neurogene holds RMAT and participates in the FDA START pilot. Two ESGCT posters were presented on October 9, 2025.
Neurogene (Nasdaq: NGNE) said company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025 at 7:00 a.m. ET.
Format includes a fireside chat plus investor meetings. A live webcast and a limited-time replay will be available from the Investor Relations events section on Neurogene’s website.
Neurogene (Nasdaq: NGNE) announced on October 3, 2025 that its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 9,390 shares for four new employees, effective October 1, 2025.
The grants were made under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price equals Neurogene’s closing stock price on the grant date. Vesting is over four years: 25% at the first anniversary of the vesting commencement date, then equal installments every three months over the following 36 months, subject to continued employment.
Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced the approval of inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 47,040 shares of common stock for six new employees on September 3, 2025.
The grants, made under the company's 2025 Inducement Plan, will vest over four years with 25% vesting on the first anniversary and the remainder vesting quarterly over the following 36 months. The exercise price equals the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
Neurogene (Nasdaq: NGNE) reported Q2 2025 financial results and provided updates on its NGN-401 gene therapy program for Rett syndrome. The company has completed dosing in its Phase 1/2 trial and received FDA agreement on key elements of the Embolden™ registrational trial, with trial initiation activities already underway.
Financial highlights include a strong cash position of $274.5 million, providing runway into early 2028. Q2 2025 saw a net loss of $22.0 million, with R&D expenses of $19.4 million and G&A expenses of $6.7 million. The company plans to report updated clinical efficacy and safety data from the Phase 1/2 trial in H2 2025.